ReviewSmall science2025
Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.
Review in Small science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Upconversion nanoplatform unlocks the theranostic potential of Lu-177 radiotherapy via c-MET axis targeting in head and neck squamous cell carcinoma.Materials today. Bio · 2026Article
- Engineering intrinsically radiolabeled nanoparticles for imaging and therapy: a decade of design strategies and insights.RSC advances · 2026Review
- Multifunctional Nano-Contrast Agent Carriers: From Traditional Platforms to Next-Generation Theranostic Applications in Molecular Imaging.Biomedicines · 2026Review
- Application of multimodal nanotechnology and standardized nursing management in ventricular arrhythmia.Biomedical engineering online · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in nanotechnology over the past few decades have offered tremendous possibilities toward cancer theranostics. Radiolabeled nanogels (NGs) represent a promising nanoplatform in this direction, offering a multifunctional toolset for both imaging and therapeutic interventions. This review encapsulates the progressions and potential of radiolabeled NGs in the realm of cancer research. Firstly, multifunctional radiolabeled NGs serve as potent contrast agents for multimodality imaging, enabling precise visualization of tumor sites through various techniques such as positron emission tomography, single-photon emission computed tomography, optical imaging and magnetic resonance imaging. Furthermore, by incorporating more than one therapeutic payload such as chemotherapeutic drugs, nucleic acids, and/or therapeutic radionuclides, they enable synergistic treatment modalities that address the heterogeneity of cancer cells and their microenvironment. This combination approach allows for enhanced therapeutic efficacy while minimizing systemic toxicity, addressing challenges associated with conventional cancer therapies. Furthermore, the radiolabeling of NGs provides a means for real-time monitoring of therapeutic distribution and pharmacokinetics, offering valuable insights into treatment response and optimization. Overall, radiolabeled NGs represent a promising platform for the integration of multimodality imaging and combination therapy in the fight against cancer with increased efficacy, reduced toxicity, and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.